SCHEMBL190089

SCHEMBL190089

Cc1csc(N)c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
PRKCZ Q05513 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 4/20 0.40
HSD17B10 Q99714 4/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
DAO P14920 2/20 0.38
NOTUM Q6P988 1/20 0.38
LDHA P00338 1/20 0.37
LDHB P07195 1/20 0.37
MPI P34949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13764542 0.83 ALDH1A1 (0.40) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL944792 0.83 ALDH1A1 (0.47) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL8566481 0.79 ALDH1A1 (0.56) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL18080714 0.78 PRKCZ (0.42) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL1041240 0.78 ALDH1A1 (0.59) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL4236884 0.77 POLB (0.44) ALDH1A1MEN1KMT2AMAPTMAPK1
SCHEMBL5154417 0.77 ALDH1A1 (0.40) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL15047075 0.76 TSHR (0.43) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL19260334 0.76 PRKCZ (0.40) ALDH1A1PRKCZMEN1KMT2AHPGD
SCHEMBL6492073 0.76 POLB (0.53) ALDH1A1KMT2AMAPTPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3967714-B1 VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES SEKISUI CHEMICAL CO LTD (JP) 2026-01-07 EP claimed
US-20260042780-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC (US) 2026-02-12 US disclosed
US-12421243-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) 2025-09-23 US disclosed
US-20240408093-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2024-12-12 US disclosed
CN-112334191-B Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms 普林特商业服务有限公司 2024-12-10 CN disclosed
US-20240270752-A1 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) 2024-08-15 US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 US disclosed
CN-117924285-A Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms 普林特商业服务有限公司 2024-04-26 CN disclosed
US-11845758-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) 2023-12-19 US disclosed
EP-4276102-A2 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS Printnet Kereskedelmi és Szolgáltató Kft. (HU) 2023-11-15 EP disclosed
EP-0587814-A1 SUBSTITUTED PYRIMIDINONES BEARING ACIDIC FUNCTIONAL GROUPS AS ANGIOTENSIN II ANTAGONISTS MERCK & CO. INC. (US) 1994-03-23 EP disclosed
CN-1077957-A Antimicrobial compounds ZENECA LTD (GB) 1993-11-03 CN disclosed
WO-1992020687-A1 SUBSTITUTED PYRIMIDINONES BEARING ACIDIC FUNCTIONAL GROUPS AS ANGIOTENSIN II ANTAGONISTS MERCK & CO., INC. (US) 1992-11-26 WO disclosed
US-4692461-A PLANT PROTECTION BAYER AKTIENGESELLSCHAFT (DE) 1987-09-08 US disclosed
EP-0227431-A1 Heterocyclic amides BEECHAM GROUP PLC (GB) 1987-07-01 EP disclosed
EP-0025643-B1 OXO-PYRIDO(1,2-A)THIENOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS WARNER-LAMBERT COMPANY (US) 1983-08-17 EP disclosed
US-4332947-A TREATMENT OF ALLERGIES WARNER-LAMBERT COMPANY (US) 1982-06-01 US disclosed
US-4287340-A USEFUL AS ANTIALLERGENS WARNER-LAMBERT COMPANY (US) 1981-09-01 US disclosed
EP-0025643-A1 Oxo-pyrido(1,2-a)thienopyrimidine compounds, processes for their production, and pharmaceutical compositions containing said compounds WARNER-LAMBERT COMPANY (US) 1981-03-25 EP disclosed
US-4230707-A ANTIALLERGENS WARNER-LAMBERT COMPANY (US) 1980-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845758-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms MYH2, MYLK2, MYO1B ALDH1A1 2854/4885PRKCZ 326/4885MEN1 2122/4885
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CD ALDH1A1 2457/4885PRKCZ 142/4885MEN1 883/4885
US-20240270752-A1 PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS MYH2, MYLK2, MYO1B ALDH1A1 2854/4885PRKCZ 326/4885MEN1 2122/4885
US-20240408093-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE FGFR3, FGFR1, ERBB3 ALDH1A1 4423/4885PRKCZ 417/4885MEN1 3687/4885
US-20260042780-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PTEN, PIK3C2A, PIK3CA ALDH1A1 3910/4885PRKCZ 33/4885MEN1 2821/4885
US-12421243-B2 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms MYH2, MYLK2, MYO1B ALDH1A1 2854/4885PRKCZ 326/4885MEN1 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.